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Preamble
The year 2015 was once more filled with exciting and 
important novel developments in the field of invasive 
electrophysiology and implantable cardiac devices. These 
include technical innovation, novel molecular and cellular 
insights, and presentation of large randomized clinical trials 
as well as important ‘real-world’ registries. In addition, 
several new guidelines surfaced in 2015, including those for 
the treatment of ventricular arrhythmias and prevention of 
sudden cardiac death. It is virtually impossible to cover all 
novel developments that would merit discussion in this type 
of overview; as a result, the authors had to make a selection, 
focusing on several important developments with direct 
implications for daily clinical practice.
Cardiac arrhythmias and catheter ablation
Atrial fibrillation
Catheter ablation of atrial fibrillation (AF) remained in 
focus of clinical studies and large-scale trials. The use of 
force-sensing ablation catheter technologies seems to improve 
the induction of durable atrial lesions and was shown to 
significantly reduce AF recurrence rate after catheter ablation 
in a meta-analysis mainly made of non-randomized trials.1 This 
technology will become standard for AF catheter ablation in 
the future. A word of caution: there is growing evidence that 
more extensive ablation in the atria does not per se improve 
the rhythm outcome after AF catheter ablation. The Minimax 
Trial compared two ablation strategies for pulmonary vein 
isolation (PVI) in 234 patients who underwent catheter 
ablation of paroxysmal AF: circumferential antral PVI alone 
(‘minimal’) vs. PVI with intravenous ridge ablation to achieve 
individual PVI (‘maximal’). After a mean follow-up of 17 ± 
8 months, freedom from AF after limited ‘minimal’ ablation 
was not worse compared with more extensive ‘maximal’ 
ablation (70 vs. 62%; p = 0.25).2 Previous data indicated 
that adenosine-guided detection of dormant pulmonary vein 
re-conduction and subsequent re-isolation of the veins can 
be successfully applied to improve outcome of AF catheter 
ablation.3 However, a much bigger randomized trial published 
in European Heart Journal now questioned the usefulness of 
adenosine testing: in the Japanese UNDER anti-tachycardia 
pacing (ATP) Trial, 2113 patients were randomized to either 
adenosine challenge or control and no difference in AF 
recurrence rate was shown at 1 year.4 The reasons for the 
contradictory results reported from these two multi-centre, 
randomized trials are unclear at present and deserve further 
investigation. Treatment with anti-arrhythmic drugs after 
catheter ablation was shown to reduce the AF recurrence 
90 days after catheter ablation in the EAST AF trial, however, 
at 1 year there was no difference in arrhythmia recurrence 
between treatment and control group.5 These results are 
quite in line with the data of the AmioCat Trial.6 In AmioCat 
patients were randomized to amiodarone or placebo for 8 
weeks after AF catheter ablation. While amiodarone treatment 
reduced hospitalizations and cardioversions in the 3-month 
post-ablation blanking period, there was no difference in AF 
recurrence rate at 6-month follow-up (39 vs., 48%; p = 0.18). 
Thus, anti-arrhythmic drugs may prevent early AF recurrences 
after ablation but may not promote a better atrial re-modelling 
resulting in a higher sinus rhythm rate during follow-up. The 
5-year follow-up data of the MANTRA-PAF Trial were reported 
during the ESC Congress in London: MANTRA-PAF evaluated 
the comparative effects of first-line radiofrequency catheter 
ablation of AF with anti-arrhythmic drug therapy. At 2-year 
follow-up, there was no difference in cumulative AF burden 
between the ablation and anti-arrhythmic drug group, while 
the burden of AF was significantly lower in the ablation group 
(90th percentile, 9 vs. 18%; p = 0.007).7 However, at 5-year 
follow-up, there was a significantly higher rate of AF-free 
patients in the ablation compared the anti-arrhythmic drug 
treatment group (86 vs. 71%; p = 0.001). Also, AF burden 
was lower in the ablation compared with the drug group (p = 
0.003). Interestingly, the effects on quality of life were similar 
in both groups. These data indicate that the rhythm benefit 
resulting from catheter ablation may increase over time; 
however, it is important to understand that MANTRA-PAF was 
too small to evaluate any effect of ablation or anti-arrhythmic 
drugs on hard outcome parameters such as stroke and/or 
mortality. These questions will be open until data from the 
EAST Trial (endpoint: composite of death, stroke, and heart 
failure) and CABANA Trial (endpoint: composite of death, 
serious bleeding, disabling stroke, and cardiac arrest) are 
available.8,9 Persistent AF ablation strategy has never been 
mature enough for a consensus to emerge, neither in the past DOI: 10.1093/eurheartj/ehv725
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nor in 2015. Rotor ablation using contact phase mapping has 
been questioned,10 and CAFÉ ablation is not specific enough 
to be convincing as demonstrated by a large meta-analysis.11 In 
contrast, lifestyle modification such as weight loss is remarkably 
effective in reducing AF burden (10% loss translates into a six-
fold AF burden reduction) and in inducing reverse remodelling 
on left atrial size and left ventricular septal thickness.12
Stroke prevention
Due to the results from large-scale clinical trials, the non-
vitamin K antagonist oral anticoagulants (NOACs) are the 
preferred treatment for stroke prevention in non-valvular 
AF, as reflected in current ESC guidelines.13 As the fourth 
NOAC, edoxaban has been approved in 2015 in many 
countries including the USA, Switzerland, and Europe based 
on the results of the ENGAGE AF-TIMI 48 trial.14 During the 
year 2015, several subgroup analyses of the large NOAC 
trials have surfaced, including bleeding management and 
outcome with apixaban,15 the management of rivaroxaban 
around catheter ablation for AF (VENTURE-AF),16 and the 
outcome of amiodarone co-medication in patients receiving 
edoxaban,17 to name just a few. Virtually, all subgroups of 
the large NOAC trials indicate a consistent benefit and safety 
of these drugs compared with warfarin, further underlining 
their overall superiority. This is supported by important real-
world data (including those from a prospective registry with 
rivaroxaban, XANTUS)18 indicating efficacy and safety, which 
is in line with that observed in the randomized clinical trials.
Arguably, the most exciting novelty in the field of 
NOACs comes from the development of specific reversal 
agents (‘antidotes’). In a Phase 1 study in healthy men, the 
monoclonal antibody idarucizumab (specific for dabigatran) 
was well tolerated with no unexpected or clinically relevant 
safety concerns, and was associated with immediate, 
complete, and sustained reversal of dabigatran-induced 
anticoagulation.19 Moreover, in a Phase 3 study, idarucizumab 
was demonstrated to effectively and immediately reverse the 
anticoagulant effect of dabigatran in patients presenting with 
serious bleeding or requiring an urgent procedure.20 As a 
result, the US Food and Drug Administration has approved the 
drug in October 2015; the Committee for Medicinal Products 
for Human Use of the European Medicines Agency has also 
recently issued a positive opinion, and approval is expected by 
the end of this year or early 2016. Importantly, idarucizumab 
is ineffective against Xa-inhibitors; instead, different directly 
acting antidotes are being developed, including andexanet 
alfa and PER977. First results are also positive with these 
agents, and larger-scale clinical trials are anticipated within the 
year 2016. While these drugs clearly represent an important 
addition to our portfolio, many aspects in the practical use 
remain to be determined, including the type of patients and 
conditions requiring reversal and the time of reinstitution of 
anticoagulation. These and other issues are elegantly described 
in the 2015 updated version of the European Heart Rhythm 
Association practical guide,21 following the great success of its 
first version published in 2013.22
Will catheter ablation of AF have an impact on stroke risk? 
Novel data from a large Danish registry suggest a very low risk 
of stroke for patients after catheter ablation.23 However, these 
data do require validation in a prospective randomized trial 
before clinical practice for oral anticoagulation after catheter 
ablation may be changed.24
Ventricular arrhythmias and sudden cardiac death
Catheter ablation of ventricular tachycardia (VT) is one of 
the fastest growing fields in interventional electrophysiology25; 
the importance of diagnosing and correctly triaging VTs, 
particularly those easily amenable to catheter ablation 
(Figure 1), is a challenge faced by cardiologists on a regular 
basis. Multiple important studies have been reported within 
the last 12 months documenting the importance and increased 
utilization of VT ablation. Despite several remarkable technical 
and technological improvements and innovations such as use 
of image integration,26 novel ablation electrodes,27,28 force-
sensing technologies,29 or ultra-high density mapping,30 the 
relatively high recurrence rate of any VT after catheter 
ablation in patients with VT and structural heart disease 
remains a key challenge. As evident from recent multi-centre 
data, non-inducibility of any VT at the end of the ablation 
is probably the best endpoint for the procedure and should 
be targeted.31 In addition, non-inducibility when supported 
by elimination of abnormal potentials may also have an 
impact on survival as well.32,33 Most fascinating is the report 
of successful ‘ablation’ of Brugada syndrome. The idea to 
treat Brugada patients at risk of sudden cardiac death with 
an interventional ablation procedure is further advanced by a 
recent report from Brugada et al.34 In their series, 13 patients 
underwent epicardial mapping and right ventricular abnormal 
electrograms were identified in all of them. Catheter ablation 
normalized the ECG and abolished pre-existing typical 
ECG changes induced by flecainide. However, despite all 
enthusiasm, it is unclear whether or not these ablation effects 
have an impact on spontaneous VT/ventricular fibrillation (VF) 
and/or risk of sudden cardiac death. The new ESC Guidelines 
for the treatment of ventricular arrhythmias and prevention of 
sudden cardiac death were presented during the ESC congress 
in London.35 These guidelines provide up-to-date state-of-
the-art summary of current knowledge and best practice 
treatment in this field.
Cardiac electronic devices
Leadless pacemakers
One of the main trends for cardiac devices in the year 2015 
was the continued movement towards the abandonment of 
intravascular leads. After an initially tedious start, leadless 
single-chamber pacemakers have finally arrived in daily clinical 
practice. Early results from the 140 patients receiving the 
Medtronic MICRA leadless pacemaker system demonstrated 
a favourable efficacy and safety profile.36 During a mean 
follow-up of 1.9 ± 1.8 months (i.e. covering primarily the 
perioperative and early postoperative period), no unanticipated 
serious adverse device events were observed, including no 
device dislodgement and only one pericardial effusion without 
tamponade (resulting in prolonged hospitalization). Of note, 
the latter occurred in a patient in whom the device needed 
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to be repeatedly repositioned (18×). In the majority of 
patients (81%), however, the device was properly placed with 
no or only one repositioning. During follow-up, electrical 
values including pacing thresholds, impedance, and sensing 
remained stable and favourable, resulting in an anticipated 
battery longevity of 12.6 years (range 8.6–14.4).36 As a result 
of these findings, the MICRA system received CE mark in 
the summer of 2015, followed by careful rollout to selected 
centres and operators after undergoing comprehensive in 
vivo and ex vivo training. These positive initial results were 
mirrored in a larger group of 725 patients, of whom 719 
(99.2%) underwent successful implantation.37 Electrical 
values (threshold, sensing, and impedance) were favourable 
in 292 of 297 patients with paired 6-month data. There 
were 28 major complications in 25 of 725 patients [4.0%, 
including 11 (1.9%) traumatic cardiac perforation or effusion 
and 1 death (0.1%)]. These numbers compared favourably 
with historic controls undergoing transvenous pacemaker 
implantation. Importantly, no device dislodgements were 
observed.37 Results of the second available single-chamber 
transcatheter pacing system, the Nanostim (St Jude Medical), 
were equally presented and published this year.38 In the 
first 526 patients undergoing implantation, the system was 
successfully implanted in 504 (95.8%). Of the 300 patients 
who completed 6-month follow-up, the primary efficacy 
outcome (acceptable electrical values) was reached in 90%. 
Of the total cohort of 526 patients, serious device-related 
adverse events occurred in 6.5% of patients, including 
cardiac tamponade in 5 (1.0%), device dislodgement in 
6 (in 1.5%), and device migration during implantation 
owing to inadequate fixation in 2 patients (0.4%). Further 
experience with both leadless pacing systems will show 
how they compare in even larger populations and in daily 
clinical practice.
Patients with a typical single-chamber pacemaker 
indication currently represent the primary population 
for leadless pacers, i.e. permanent AF with symptomatic 
bradycardia and/or AV block. Future studies and real-world 
experience will show how these device behave long term 
(including the novel rate-adaptive sensor system); first 
personal experiences are encouraging. The development 
for more advanced systems is ongoing, including dual-
Figure 1 – Twelve-lead electrocardiogram morphology of different sites of origin in idiopathic ventricular tachycardia.  RVOT: right ventricular outflow tract; RCC: right 
coronary cusp; R–L com: right–left coronary cusp commissure; LCC: left coronary cusp; AMC: aortomitral continuity; TV: tricuspid annulus; MV: mitral annulus; APM: 
anterior PAP; PPM: posterior PAP; LPF: left posterior fascicle; LAF: left anterior fascicle; GCV: greater cardiac vein; AIV: anterior inter-ventricular vein. Reproduced from 
Tanawuttiwat et al.,25 reprinted with kind permission from Tanawuttiwat et al.25 This Figure has been reprinted by permission of Oxford University Press on behalf of the 
European Society of Cardiology.
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chamber pacemakers, cardiac resynchronization therapy, 
and communication with the subcutaneous implantable 
cardioverter defibrillator (ICD).
Implantable cardioverter defibrillator therapy and 
implant-based telemonitoring
Implantable cardioverter defibrillator testing is no longer 
necessary during routine and uncomplicated ICD implantation: 
in the Nordic ICD Trial, 1077 patients were randomly assigned 
to first time ICD implantation with (n = 540) or without 
(n = 537) testing of defibrillation threshold.39 Defibrillation 
efficacy was not different between both groups during follow-
up. Similarly, in the SIMPLE trial of 2500 patients, routine 
defibrillation testing did not result in a reduction in arrhythmic 
deaths during a mean follow-up of 3.1 years.40
Almost all pacemakers and defibrillators that are 
currently available have the technical option for remote 
monitoring.41 Previous results from randomized clinical 
trials and analysis from big data sets indicated that these 
technologies may have beneficial effects when applied 
appropriately.42 However, recent data from the Optilink 
HF Trial reported at the ESC Congress in London showed 
disappointing results: the trial randomized 1002 patients 
with heart failure and an indication for ICD implantation to 
remote automated pulmonary congestion alert ‘on’ (n = 505) 
or ‘off’ (n = 497). After 18 months of follow-up, there was 
no significant difference between groups in primary endpoint, 
which was a composite of all-cause death and cardiovascular 
hospitalizations. More promising data are derived from the 
follow-up report of the CHAMPION Trial that assessed the 
efficacy of automatic pulmonary pressure measurement in 
heart failure patients to guide and optimize heart failure 
therapy.43 The superiority of the treatment group over the 
control group previously reported was maintained for an 
additional 13 months to the end of the Randomized Access 
Period with a significant reduction of heart failure-related 
hospitalizations by 33% and of all-cause hospitalizations 
by 16%. Second, the good results in the treatment group 
were maintained during an Open Access Period of another 
12 months, during which no increase in hospitalizations 
was observed. Most importantly, heart failure-related 
hospitalizations and all-cause hospitalizations in the former 
control group were reduced significantly by 48 and 21%, 
respectively, after pulmonary artery pressure information 
became available to guide therapy during the Open Access 
Period. Thus, implant-based remote telemonitoring seems 
highly promising to support heart failure therapy and it will 
be just a matter of time when haemodynamic sensors will 
be combined with pacemakers, defibrillators, and cardiac 
resynchronization devices.
Subcutaneous implantable cardioverter defibrillators
Ever since its approval in 2009, the subcutaneous ICD 
(S-ICD) system has increasingly gained attention and attraction. 
Indeed, its complete lack of intravascularly placed electrodes is 
potentially associated with a substantial reduction in morbidity 
(and mortality) due to lead complications associated with 
currently used ‘classical’ transvenous ICD systems. In 2015, 
the new generation EMBLEM S-ICD System was approved, 
the main feature of which is its 20% thinner size combined 
with a 40% longer life expectancy when compared with the 
previous S-ICD system. At the same time, novel algorithms are 
being developed to overcome the risk of inadequate shock 
deliveries.44,45 Recently published registry results have indicated 
a decreasing risk of complications, suboptimal programming, 
and (to a lesser degree) inadequate shock deliveries with 
increasing experience and volume.46 In addition, the same 
registries demonstrated a high efficacy for the termination 
of VT and VF, with 90.1% of events (100/111) terminated 
with one shock and 98.5% (109/111) terminated within the 
available five shocks.47 As a result of these favourable data, the 
use of the S-ICD has, for the first time, been incorporated into 
the guidelines for the prevention of sudden cardiac death as 
a IIa indication [level of evidence (LoE) C] as an alternative 
to standard ICD for patients without an indication for 
bradycardia pacing, cardiac resynchronization, or ATP.35 Also, 
the S-ICD may be considered (IIb, LoE C) in patients with 
difficult venous access, after the transvenous ICD removal for 
infections or in young patients with a long-term indication for 
ICD therapy.35 Indeed, the lack of possibility to deliver ATP or 
bradycardia pacing remains the most important shortcoming of 
current S-ICD devices. Combination of the S-ICD with leadless 
pacers clearly would be one of the most obvious possible 
solution to this problem. However, with evidence-based 
programming (high-rate or long-duration detection zones), the 
overall amount of delivered ATP will likely be decreasing as a 
result of both spontaneous VT termination and VTs occurring 
below the detection limit. A prospective, randomized trial 
(PRAETORIAN) comparing currently available transvenous 
and subcutaneous ICDs (i.e. without the possibility of ATP) 
has been initiated and is currently ongoing.
Wearable cardioverter defibrillator
Also for the first time, the new 2015 guidelines for the 
prevention of sudden cardiac death give recommendations 
for the use of the wearable cardioverter defibrillator 
(WCD; Figure 2). With a class IIa recommendation (LoE C), 
WCD be considered for a limited time period for patients 
with reduced EF who are at risk of sudden arrhythmic 
death, but who currently cannot receive an ICD, including 
patients post-lead removal for infection, patients with active 
myocarditis, and patients with arrhythmias in the early post-
myocardial infarction phase.35 In the absence of a randomized 
clinical trial, this recommendation was based mainly on large 
registries such as the recently published prospective registry 
of patients using the wearable defibrillator (WEARIT-II), which 
followed 2000 recipients of the WCD with a median wear 
time for 90 days.48 In this registry, a total of 120 sustained 
ventricular tachyarrhythmias (VT/VF) were observed in 41 
patients. Of these patients, 54% received appropriate WCD 
shocks, while only 10 patients (0.5%) received inappropriate 
WCD therapy.
Importantly, at the end of the individual time frame of 
WCD use, an ICD was implanted in only 840 patients (42%), 
with an improvement in EF being the most frequent reason 
for withholding ICD implantation. Given the potential cost 
saved for de novo ICD implantation as well as (potentially) 
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associated follow-up cost and cost of complications, this 
strategy may in addition also turn out cost-effective, but 
comprehensive analyses in this regard are currently lacking.
Final thoughts
In the year 2015, many interesting studies have surfaced 
in the field of invasive electrophysiology and cardiac 
devices, most of which may have (or do already have) 
important implications for daily clinical practice. Ongoing 
confirmation and expansion of these data with experience 
from the real world will be crucial to substantiate their 
efficacy and safety in the ‘real world’. Coverage of all of the 
exciting developments in one concise review is impossible; 
as such, various methods and technologies had to be 
omitted for the time being, including some preliminary 
results on the use of multi-site pacing and comparisons 
of point-by-point vs. single shot ablation. If the rate and 
quality of innovation persists, undoubtedly the year 2016 
will equally be a successful one in the field of arrhythmias.
Authors’ contributions
G.H. and J.S. drafted the manuscript, and G.H., J.S., P.J. 
made critical revision of the manuscript for key intellectual 
content.
Potential Conflict of Interest
J.S. has received consultant and/or speaker fees from 
Amgen, Astra-Zeneca, Atricure, Bayer, Biosense Webster, 
Figure 2 – Wearable cardioverter defibrillator. Model of a wearable cardioverter defibrillator (images courtesy of J.S., reprinted with kind permission and patient consent). 
This Figure has been reprinted by permission of Oxford University Press on behalf of the European Society of Cardiology.
Biotronik, Boehringer-Ingelheim, Boston Scientific, Bristol-
Myers Squibb, Cook Medical, Daiichi Sankyo, Medtronic, 
Pfizer, Sanofi-Aventis, Sorin, St Jude Medical, and Zoll. J.S. 
is co-director von CorXL. He reports grant support through 
his institution from Bayer Healthcare, Biosense Webster, 
Biotronik, Boston Scientific, Daiichi Sankyo, Medtronic, and 
St Jude Medical. G.H. has received research grants from 
Biotronik, Boston Scientific, and St Jude Medical through 
the University Leipzig/Heart Center. P.J. reports consultancy 
honoraria and lecture fees from Biosense Webster, St. Jude 
Medical, and Boston Scientific; he reports stock options 
for Cardio Insight.
Copyright
First published in European Heart Journal [Volume 37, 
Issue 7, 14 february, DOI: 10.1093/eurheartj/ehv725] and 
reproduced with permission from Oxford University Press 
on behalf of the European Society of Cardiology. All rights 
reserved. © The Author 2016. If you wish to reproduce, 
reuse or distribute this article in any way, please contact 
journals.permissions@oup.com to request permission.
Translation
Oxford University Press, and the European Society of 
Cardiology are not responsible or in any way liable for 
the accuracy of the translation. A Sociedade Brasileira de 
Cardiologia is solely responsible for the translation in this 
publication.
1. Shurrab M, Di Biase L, Briceno DF, Kaoutskaia A, Haj-Yahia S, Newman 
D, et al. Impact of contact force technology on atrial fibrillation ablation: a 
meta-analysis. J Am Heart Assoc. 2015;4(9):e002476.
2. McLellan AJ, Ling LH, Azzopardi S, Lee GA, Lee G, Kumar S, et al. A 
minimal or maximal ablation strategy to achieve pulmonary vein isolation 
for paroxysmal atrial fibrillation: a prospective multi-centre randomized 
controlled trial (the MINIMAX study). Eur Heart J. 2015;36(28):1812-21.
3. Macle L, Khairy P, Weerasooriya R, Novak P, Verma A, Willems S, et al; ADVICE 
trial investigators. Adenosine-guided pulmonary vein isolation for the treatment 
of paroxysmal atrial fibrillation: an international, multicentre, randomised 
superiority trial. Lancet 2015;386(9994):672-9.
4. Kobori A, Shizuta S, Inoue K, Kaitani K, Morimoto T, Nakazawa Y, et al; UNDER-
ATP Trial Investigators. Adenosine triphosphate-guided pulmonary vein 
isolation for atrial fibrillation: the unmasking dormant electrical reconduction 
by adenosine triphosphate (under-ATP) trial. Eur Heart J 2015;36(46):3276-87.
References
389
Editorial
Steffel et al.
The year in cardiology 2015: arrhythmias and device therapy
Arq Bras Cardiol. 2016; 107(5):385-391
5. Kaitani K, Inoue K, Kobori A, Nakazawa Y, Ozawa T, Kurotobi T, et al; 
EAST-AF Trial Investigators. Efficacy of antiarrhythmic drugs short-term 
use after catheter ablation for atrial fibrillation (EAST-AF) trial. Eur Heart J. 
2016;37(7):610-8.
6. Darkner S, Chen X, Hansen J, Pehrson S, Johannessen A, Nielsen 
JB, et  a l .  Recurrence of arrhythmia fol lowing short- term oral 
amiodarone after catheter ablation for atrial fibrillation: a double-blind, 
randomized, placebo-controlled study (AMIO-CAT trial). Eur Heart J. 
2014;35(47):3356-64.
7. Cosedis Nielsen J, Johannessen A, Raatikainen P, Hindricks G, Walfridsson 
H, Kongstad O, et al. Radiofrequency ablation as initial therapy in 
paroxysmal atrial fibrillation. N Engl J Med. 2012;367(17):1587-95.
8. Aliot E, Brandes A, Eckardt L, Elvan A, Gulizia M, Heidbuchel H, et al. 
The EAST study: redefining the role of rhythmcontrol therapy in atrial 
fibrillation: EAST, the early treatment of atrial fibrillation for stroke 
prevention trial. Eur Heart J. 2015;36(5):255-6.
9. M o r e n o  J ,  Z a m o r a n o  J L .  T h e  C A B A N A  t r i a l .  E u r  H e a r t  J . 
2014;35(29):1908-9.
10. Benharash P, Buch E, Frank P, Share M, Tung R, Shivkumar K, et al. 
Quantitative analysis of localized sources identified by focal impulse 
and rotor modulation mapping in atrial fibrillation. Circ Arrhythm 
Electrophysiol. 2015;8(3):554-61.
11. Providencia R, Lambiase PD, Srinivasan N, Ganesh Babu G, Bronis K, 
Ahsan S, et al. Is there still a role for complex fractionated atrial electrogram 
ablation in addition to pulmonary vein isolation in patients with paroxysmal 
and persistent atrial fibrillation? Meta-analysis of 1415 patients. Circ 
Arrhythm Electrophysiol. 2015;8(5):1017-29.
12. Pathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong 
CX, et al. Long-term effect of goal-directed weight management in an atrial 
fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol 
2015;65(20):2159-69.
13. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al. 
2012 focused update of the ESC guidelines for the management of atrial 
fibrillation: an update of the 2010 ESC guidelines for the management of 
atrial fibrillation developed with the special contribution of the European 
Heart Rhythm Association. Europace. 2012;14(10):1385-413.
14. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et 
al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients 
with atrial fibrillation. N Engl J Med. 2013;386(22):2093-104.
15. Held C, Hylek EM, Alexander JH, Hanna M, Lopes RD, Wojdyla DM, et 
al. Clinical outcomes and management associated with major bleeding in 
patients with atrial fibrillation treated with apixaban or warfarin: insights 
from the ARISTOTLE trial. Eur Heart J. 2015;36(20):1264-72.
16. Cappato R, Marchlinski FE, Hohnloser SH, Naccarelli GV, Xiang J, Wilber 
DJ, et al; VENTURE-AF Investigators. Uninterrupted rivaroxaban vs. 
uninterrupted vitamin K antagonists for catheter ablation in non-valvular 
atrial fibrillation. Eur Heart J. 2015;36(28):1805-11.
17. Steffel J, Giugliano RP, Braunwald E, Murphy SA, Atar D, Heidbuchel 
H, et al. Edoxaban vs. warfarin in patients with atrial fibrillation on 
amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur 
Heart J. 2015;36(33):2239-45.
18. Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, et al; XANTUS 
Investigators. XANTUS: a real-world, prospective, observational study of 
patients treated with rivaroxaban for stroke prevention in atrial fibrillation. 
Eur Heart J. 2016;37(14):1145-53.
19. Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, et al. 
Safety, tolerability, and efficacy of idarucizumab for the reversal of 
the anticoagulant effect of dabigatran in healthy male volunteers: a 
randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 
2015;386(9994):680-90.
20. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et 
al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511-20.
21. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, et al. 
Advisors. Updated European Heart Rhythm Association practical guide on the 
use of non-vitamin K antagonist anticoagulants in patients with non-valvular 
atrial fibrillation. Europace. 2015;17(10):1467-507.
22. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et 
al. EHRA practical guide on the use of new oral anticoagulants in patients 
with non-valvular atrial fibrillation: executive summary. Eur Heart J. 
2013;34(27):2094-106.
23. Karasoy D, Gislason GH, Hansen J, Johannessen A, Kober L, Hvidtfeldt 
M, et al. Oral anticoagulation therapy after radiofrequency ablation of 
atrial fibrillation and the risk of thromboembolism and serious bleeding: 
long-term follow-up in nationwide cohort of Denmark. Eur Heart J. 
2015;36(5):307-14a.
24. Kirchhof P, Purmah Y, Verma A. Oral anticoagulation after catheter ablation of 
atrial fibrillation: caught in the attribution trap? Eur Heart J. 2015;36(5):267-9. 
25. Tanawuttiwat T, Nazarian S, Calkins H. The role of catheter ablation in the 
management of ventricular tachycardia. Eur Heart J. 2016;37(7):594-609.
26. Andreu D, Ortiz-Perez JT, Fernandez-Armenta J, Guiu E, Acosta J, Prat-
Gonzalez S, et al. 3D delayed-enhanced magnetic resonance sequences 
improve conducting channel delineation prior to ventricular tachycardia 
ablation. Europace. 2015;17(6):938-45.
27. Berte B, Cochet H, Magat J, Naulin J, Ghidoli D, Pillois X, et al. Irrigated 
needle ablation creates larger and more transmural ventricular lesions 
compared to standard unipolar ablation in an ovine model. Circ Arrhythm 
Electrophysiol. 2015;8(6):1498-506.
28. Berte B, Relan J, Sacher F, Pillois X, Appetiti A, Yamashita S, et al. Impact of 
electrode type on mapping of scar-related VT. J Cardiovasc Electrophysiol. 
2015 Jul 22. [Epub ahead of print].
29. Jesel L, Sacher F, Komatsu Y, Daly M, Zellerhoff S, Lim HS, et al. 
Characterization of contact force during endocardial and epicardial 
ventricular mapping. Circ Arrhythm Electrophysiol. 2014;7(6):1168-73.
30. Hooks DA, Yamashita S, Capellino S, Cochet H, Jais P, Sacher F. Ultra-
rapid epicardial activation mapping during ventricular tachycardia using 
continuous sampling from a high-density basket (ORION(TM)) catheter. J 
Cardiovasc Electrophysiol. 2015;26(10):1153-4.
31. Yokokawa M, Kim HM, Baser K, Stevenson W, Nagashima K, Della Bella P, 
et al. Predictive value of programmed ventricular stimulation after catheter 
ablation of post-infarction ventricular tachycardia. J Am Coll Cardiol. 
2015;65(18):1954-9.
32. Komatsu Y, Maury P, Sacher F, Khairy P, Daly M, Lim HS, et al. Impact of 
substrate-based ablation of ventricular tachycardia on cardiac mortality 
in patients with implantable cardioverter-defibrillators. J Cardiovasc 
Electrophysiol. 2015 Sep 1. [Epub ahead of print].
33. Dinov B, Arya A, Schratter A, Schirripa V, Fiedler L, Sommer P, et al. 
Catheter ablation of ventricular tachycardia and mortality in patients with 
nonischemic dilated cardiomyopathy: can noninducibility after ablation 
be a predictor for reduced mortality? Circ Arrhythm Electrophysiol. 
2015;8(3):598-605.
34. Brugada J, Pappone C, Berruezo A, Vicedomini G, Manguso F, Ciconte G, 
et al. Brugada syndrome phenotype elimination by epicardial substrate 
ablation. Circ Arrhythm Electrophysiol. 2015;8(6):1373-81.
35. Priori SG, Blomstrom-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm 
J, et al. 2015 ESC guidelines for the management of patients with ventricular 
arrhythmias and the prevention of sudden cardiac death: the Task Force for 
the Management of Patients with Ventricular Arrhythmias and the Prevention 
of Sudden Cardiac Death of the European Society of Cardiology (ESC). 
Endorsed by: Association for European Paediatric and Congenital Cardiology 
(AEPC). Eur Heart J. 2015;36(41):2793-867.
36. Ritter P, Duray GZ, Steinwender C, Soejima K, Omar R, Mont L, et al; Micra 
Transcatheter Pacing Study Group. Early performance of a miniaturized 
leadless cardiac pacemaker: the MICRA Transcatheter Pacing Study. Eur 
Heart J. 2015;36(37):2510-9.
390
Editorial
Steffel et al.
The year in cardiology 2015: arrhythmias and device therapy
Arq Bras Cardiol. 2016; 107(5):385-391
37. Reynolds D, Duray GZ, Omar R, Soejima K, Neuzil P, Zhang S, et al; Micra 
Transcatheter Pacing Study Group. A leadless intracardiac transcatheter 
pacing system. N Engl J Med. 2016;374(16):533-41.
38. Reddy VY, Exner DV, Cantillon DJ, Doshi R, Bunch TJ, Tomassoni GF, et al; 
LEADLESS II Study Investigators. Percutaneous implantation of an entirely 
Intracardiac Leadless Pacemaker. N Engl J Med. 2015;373(12):1125-35.
39. Bansch D, Bonnemeier H, Brandt J, Bode F, Svendsen JH, Taborsky M, et 
al; NORDIC ICD Trial Investigators. Intra-operative defibrillation testing 
and clinical shock efficacy in patients with implantable cardioverter-
defibrillators: the NORDIC ICD randomized clinical trial. Eur Heart J. 
2015;36(37):2500-7.
40. Healey JS, Hohnloser SH, Glikson M, Neuzner J, Mabo P, Vinolas X, et 
al; Shockless IMPLant Evaluation [SIMPLE] Investigators. Cardioverter 
defibrillator implantation without induction of ventricular fibrillation: 
a single-blind, non-inferiority, randomised controlled trial (SIMPLE). 
Lancet. 2015;385(9970):785-91.
41. Varma N, Ricci RP. Telemedicine and cardiac implants: what is the 
benefit? Eur Heart J. 2013;34(25):1885-95.
42. Varma N, Piccini JP, Snell J, Fischer A, Dalal N, Mittal S. The relationship 
between level of adherence to automatic wireless remote monitoring 
and survival in pacemaker and defibrillator patients. J Am Coll Cardiol 
2015;65(24):2601-10.
43. Abraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, 
Adamson PB; CHAMPION Trial Study Group. Sustained efficacy of pulmonary 
artery pressure to guide adjustment of chronic heart failure therapy: 
complete follow-up results from the CHAMPION randomised trial. Lancet. 
2016;387(10017):453-61.
44. Brisben AJ, Burke MC, Knight BP, Hahn SJ, Herrmann KL, Allavatam V, et al. A 
new algorithm to reduce inappropriate therapy in the S-ICD system. J Cardiovasc 
Electrophysiol. 2015;26(4):417-23.
45. Lambiase PD, Barr C, Theuns DA, Knops R, Neuzil P, Johansen JB, et al. 
EFFORTLESS Investigators. Worldwide experience with a totally subcutaneous 
implantable defibrillator: early results from the EFFORTLESS S-ICD registry. Eur 
Heart J. 2014;35(25):1657-65.
46. Knops RE, Brouwer TF, Barr CS, Theuns DA, Boersma L, Weiss R, et al; IDE and 
EFFORTLESS investigators. The learning curve associated with the introduction 
of the subcutaneous implantable defibrillator. Europace. 2016;18(7):1010-5.
47. Burke MC, Gold MR, Knight BP, Barr CS, Theuns DA, Boersma LV, et al. Safety 
and efficacy of the totally subcutaneous implantable defibrillator: 2-year results 
from a pooled analysis of the IDE study and effortless registry. J Am Coll Cardiol. 
2015;65(16):1605-15.
48. Kutyifa V, Moss AJ, Klein H, Biton Y, McNitt S, MacKecknie B, et al. Use of the 
wearable cardioverter defibrillator in high-risk cardiac patients: data from the 
prospective registry of patients using the wearable cardioverter defibrillator 
(WEARIT-II registry). Circulation. 2015;132(17):1613-9.
391
